or Try an Advanced Search...

    Entospletinib Stocks List

    Symbol Grade Name % Change
    AFMD F Affimed Therapeutics B.V. -1.65
    KRON F Kronos Bio, Inc. 1.16
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Solid Tumors Acute Myeloid Leukemia Biology Blastoma CD19 Cancer Cancer Therapeutics Chronic Lymphocytic Leukemia Clinical Development Cyclin Dependent Kinase Enzymes Epidermal Growth Factor Receptor Glioblastoma Head And Neck Cancer Hematologic Malignancies Hodgkin Lymphoma Immunotherapies Lymphocytic Leukemia Lymphoma

    Related ETFs - A few ETFs which own one or more of the above listed Entospletinib stocks.

    Symbol Grade Name Weight
    IWC B iShares Microcap ETF 0.01
    VTI A Vanguard Total Stock Market ETF 0.0
    VXF B Vanguard Extended Market ETF 0.0
    View all Entospletinib ETFs...
    Compare ETFs
    Compare IWC to VTI Compare IWC to VXF Compare VTI to VXF

        Entospletinib Stocks Recent News

        Date Stock Title
        Nov 19 AFMD Is Affimed N.V. (AFMD) the Best German Stock to Buy Now?
        Nov 17 KRON Deal Dispatch: Shell, Unilever And More Are On The Sell Side; The Onion Makes Alex Jones Cry Foul
        Nov 16 KRON Kronos Bio Third Quarter 2024 Earnings: Beats Expectations
        Nov 15 AFMD Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges with ...
        Nov 14 KRON Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Solid Tumors Acute Myeloid Leukemia Biology Blastoma CD19 Cancer Cancer Therapeutics Chronic Lymphocytic Leukemia Clinical Development Cyclin Dependent Kinase Enzymes Epidermal Growth Factor Receptor Glioblastoma Head And Neck Cancer Hematologic Malignancies Hodgkin Lymphoma Immunotherapies Lymphocytic Leukemia Lymphoma
        Entospletinib

        Entospletinib is an experimental drug for the treatment of various types of cancer under development by Gilead Sciences. It is an inhibitor of spleen tyrosine kinase (Syk). It has entered clinical trials for acute myeloid leukaemia (AML), chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), graft-versus-host disease (GvHD), hematological malignancies, mantle cell lymphoma (MCL), and non-Hodgkin lymphoma (NHL).

        More about Entospletinib
        Browse All Tags